Linda C Laux1, E Martina Bebin2, Daniel Checketts3, Michael Chez4, Robert Flamini5, Eric D Marsh6, Ian Miller7, Kathryn Nichol8, Yong Park9, Eric Segal10, Laurie Seltzer11, Jerzy P Szaflarski2, Elizabeth A Thiele12, Arie Weinstock13. 1. Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA. Electronic address: LLaux@luriechildrens.org. 2. University of Alabama Birmingham, Birmingham, AL, USA. 3. GW Research Ltd, London, UK. 4. Sutter Health, Roseville, CA, USA. 5. PANDA Neurology, Atlanta, GA, USA. 6. Children's Hospital of Philadelphia, Philadelphia, PA, USA. 7. Nicklaus Children's Hospital, Miami, FL, USA. 8. Greenwich Biosciences, Carlsbad, CA, USA. 9. Augusta University Medical Center, Augusta, GA, USA. 10. Northeast Regional Epilepsy Group, Hackensack University Medical Center, Hackensack, NJ, USA. 11. University of Rochester Medical Center, Rochester, MN, USA. 12. Massachusetts General Hospital, Boston, MA, USA. 13. Oishei Children's Hospital, Buffalo, NY, USA.
Abstract
BACKGROUND: Since 2014, patients with severe treatment-resistant epilepsies (TREs) have been receiving add-on cannabidiol (CBD) in an ongoing, expanded access program (EAP), which closely reflects clinical practice. We conducted an interim analysis of long-term efficacy and tolerability in patients with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) who received CBD treatment through December 2016. METHODS: Children and adults with LGS/DS taking stable doses of antiepileptic drugs (AEDs) at baseline were included from 25 EAP sites across the United States. During the 4-week baseline period, parents/caregivers kept diaries of all countable seizure types. Patients received a pharmaceutical formulation of highly purified CBD (Epidiolex®; 100 mg/mL) in oral solution at 2-10 mg/kg/day, titrated until tolerability limit or a maximum dose of 25-50 mg/kg/day. Patient visits were every 2-4 weeks. The percentage change from baseline in median monthly convulsive (ie, major motor) and total seizures was evaluated at 12-week intervals through 96 weeks. The percentages of patients who had ≥50%, ≥75%, and 100% reduction in monthly seizures relative to the baseline period were also evaluated. Adverse events (AEs) were monitored and summarized for the safety analysis set (SAS) through 144 weeks. RESULTS: Of the 607 patients in the SAS, 58 had DS and 94 had LGS (N = 152); 455 patients had other TREs. Twenty-eight percent of LGS/DS patients withdrew, primarily owing to lack of efficacy (20%). LGS/DS patients were taking a median of 3 (0-10) concomitant AEDs. Median treatment duration was 78.3 (range, 4.1-146.4) weeks. Between weeks 12 and 96, median CBD dose ranged from 21 to 25 mg/kg/day. At 12 weeks, add-on CBD reduced median monthly major motor seizures by 50% and total seizures by 44%, with consistent reductions in both seizure types through 96 weeks. At 12 weeks, the proportions of patients with ≥50%, ≥75%, and 100% reductions in major motor seizures were 53%, 23%, and 6%; the proportions with corresponding reductions in total seizures were 46%, 26%, and 5%. Responder rates for both seizure types were consistent through 96 weeks. CBD had an acceptable safety profile; the most common AEs were somnolence (30%) and diarrhea (24%). CONCLUSIONS: Results from this interim analysis support add-on CBD as an effective long-term treatment option in LGS or DS.
BACKGROUND: Since 2014, patients with severe treatment-resistant epilepsies (TREs) have been receiving add-on cannabidiol (CBD) in an ongoing, expanded access program (EAP), which closely reflects clinical practice. We conducted an interim analysis of long-term efficacy and tolerability in patients with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) who received CBD treatment through December 2016. METHODS:Children and adults with LGS/DS taking stable doses of antiepileptic drugs (AEDs) at baseline were included from 25 EAP sites across the United States. During the 4-week baseline period, parents/caregivers kept diaries of all countable seizure types. Patients received a pharmaceutical formulation of highly purified CBD (Epidiolex®; 100 mg/mL) in oral solution at 2-10 mg/kg/day, titrated until tolerability limit or a maximum dose of 25-50 mg/kg/day. Patient visits were every 2-4 weeks. The percentage change from baseline in median monthly convulsive (ie, major motor) and total seizures was evaluated at 12-week intervals through 96 weeks. The percentages of patients who had ≥50%, ≥75%, and 100% reduction in monthly seizures relative to the baseline period were also evaluated. Adverse events (AEs) were monitored and summarized for the safety analysis set (SAS) through 144 weeks. RESULTS: Of the 607 patients in the SAS, 58 had DS and 94 had LGS (N = 152); 455 patients had other TREs. Twenty-eight percent of LGS/DS patients withdrew, primarily owing to lack of efficacy (20%). LGS/DS patients were taking a median of 3 (0-10) concomitant AEDs. Median treatment duration was 78.3 (range, 4.1-146.4) weeks. Between weeks 12 and 96, median CBD dose ranged from 21 to 25 mg/kg/day. At 12 weeks, add-on CBD reduced median monthly major motor seizures by 50% and total seizures by 44%, with consistent reductions in both seizure types through 96 weeks. At 12 weeks, the proportions of patients with ≥50%, ≥75%, and 100% reductions in major motor seizures were 53%, 23%, and 6%; the proportions with corresponding reductions in total seizures were 46%, 26%, and 5%. Responder rates for both seizure types were consistent through 96 weeks. CBD had an acceptable safety profile; the most common AEs were somnolence (30%) and diarrhea (24%). CONCLUSIONS: Results from this interim analysis support add-on CBD as an effective long-term treatment option in LGS or DS.
Authors: Terence J O'Brien; Samuel F Berkovic; Jacqueline A French; John A Messenheimer; Terri B Sebree; Marcel O Bonn-Miller; Donna L Gutterman Journal: JAMA Netw Open Date: 2022-07-01
Authors: Luigi Francesco Iannone; Gabriele Arena; Domenica Battaglia; Francesca Bisulli; Paolo Bonanni; Antonella Boni; Maria Paola Canevini; Gaetano Cantalupo; Elisabetta Cesaroni; Manuela Contin; Antonietta Coppola; Duccio Maria Cordelli; Giovanni Cricchiuti; Valentina De Giorgis; Maria Fulvia De Leva; Marta De Rinaldis; Giuseppe d'Orsi; Maurizio Elia; Carlo Andrea Galimberti; Alessandra Morano; Tiziana Granata; Renzo Guerrini; Monica A M Lodi; Angela La Neve; Francesca Marchese; Silvia Masnada; Roberto Michelucci; Margherita Nosadini; Nicola Pilolli; Dario Pruna; Francesca Ragona; Anna Rosati; Margherita Santucci; Alberto Spalice; Nicola Pietrafusa; Pasquale Striano; Elena Tartara; Laura Tassi; Amanda Papa; Claudio Zucca; Emilio Russo; Oriano Mecarelli Journal: Front Neurol Date: 2021-05-20 Impact factor: 4.003
Authors: Lyndsey L Anderson; Maia G Etchart; Dilara Bahceci; Taliesin A Golembiewski; Jonathon C Arnold Journal: Sci Rep Date: 2021-07-22 Impact factor: 4.379